Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.
Alzheimers Dement
; 20(2): 975-985, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-37830443
ABSTRACT
INTRODUCTION:
Little is known about the heterogeneous treatment effects of metformin on dementia risk in people with type 2 diabetes (T2D).METHODS:
Participants (≥ 50 years) with T2D and normal cognition at baseline were identified from the National Alzheimer's Coordinating Center database (2005-2021). We applied a doubly robust learning approach to estimate risk differences (RD) with a 95% confidence interval (CI) for dementia risk between metformin use and no use in the overall population and subgroups identified through a decision tree model.RESULTS:
Among 1393 participants, 104 developed dementia over a 4-year median follow-up. Metformin was significantly associated with a lower risk of dementia in the overall population (RD, -3.2%; 95% CI, -6.2% to -0.2%). We identified four subgroups with varied risks for dementia, defined by neuropsychiatric disorders, non-steroidal anti-inflammatory drugs, and antidepressant use.DISCUSSION:
Metformin use was significantly associated with a lower risk of dementia in individuals with T2D, with significant variability among subgroups.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Demência
/
Diabetes Mellitus Tipo 2
/
Metformina
Limite:
Humans
Idioma:
En
Revista:
Alzheimers Dement
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos